BOWEN MATTHEW

PrivateCIK: 2115025
Location

BOSTON, MA

BOWEN MATTHEW enters MONTE ROSA THERAPEUTICS, INC. with 21.60K shares plus derivative instruments

Holding both equity and derivatives at entry signals strong long-term conviction in the company.

Direct Derivatives
InsiderBOWEN MATTHEWCIK 2115025
Officer· Principal Accounting Officer
Since Apr 2026
21.60K
Baseline shares
100% direct
21.60K
Direct ownership
1 position
43.02K
Derivative underlying
8 instruments
1
Security positions
All direct
Non-Derivative Holdings1

Common Stock

Direct
Shares owned21.60K
Total
21.60K direct21.60K
Derivative Holdings8

Stock Option (Right to Buy)

Direct
Underlying security
Common Stock

Underlying shares

7.40K

Shares owned

N/A

Exercise price

15.31

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Common Stock

Underlying shares

3.70K

Shares owned

N/A

Exercise price

5.71

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Common Stock

Underlying shares

5.50K

Shares owned

N/A

Exercise price

23.99

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Common Stock

Underlying shares

9.95K

Shares owned

N/A

Exercise price

13.41

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Common Stock

Underlying shares

10.80K

Shares owned

N/A

Exercise price

7.11

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Common Stock

Underlying shares

1.50K

Shares owned

N/A

Exercise price

6.3

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Common Stock

Underlying shares

3.55K

Shares owned

N/A

Exercise price

7.78

Expiration

Exercise window

Stock Option (Right to Buy)

Direct
Underlying security
Common Stock

Underlying shares

625.00

Shares owned

N/A

Exercise price

7.5

Expiration

Exercise window

Total

Underlying

43.02K

Owned

0.00

BOWEN MATTHEW — Initial Ownership Disclosure (Form 3) Filed Apr 7, 2026 | Finecho